Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a... see more

TSX:SVA - Post Discussion

Sernova Corp > $5 or $10 buyout - Idiots
View:
Post by MedStocks2 on Jan 15, 2021 11:28pm

$5 or $10 buyout - Idiots

clearly this board is attracting some true idiots who still don't understand the real value here. The cell pouch with the immune protection tech is essentially the sim card of regenerative medicine. There are hundreds of companies doing in therapeutic cells and Sernova is the only company with a successful device for containing those cells. This company could easily be worth north of $50 a share. Given the results we saw in the press release, we could be on a very short path. The patents are solid and therapeutic cell companies are going to prefer pouring resources into cell lines and not reinventing a cell pouch. Hopefully, anyone foolish enough to think $10 is a good buyout doesn't hold enough shares to carry weight in a vote.
Comment by Redbaron2211 on Jan 15, 2021 11:58pm
Med, agree we are on a precipice of a major revolution in cell therapy.  Sernova is very well positioned to capture this.  
Comment by stockhunter1 on Jan 16, 2021 12:13am
MedStocks2...I agree fully $50 a share is easy. I have been buying for years on the potential of the device [ cell pouch ] alone. It has many applications, if you have even a small imagination. I expect a valuation in line with our PEERS before we are bought out. I also expect a bidding war for this Disruptive device. This prize will fetch plenty to be sure and many a BIG PHARMA  will be ...more  
Comment by Redbaron2211 on Jan 16, 2021 12:28am
Long term I agree 10B+ is possible.     Short term focus on revaluation with peers and a SP at $6+ is very achievable and could happen alot quicker then we think.  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse